Meeting Posters (ECCMID)

Reference No.

Document title

The antibacterial effect (ABE) of ceftolozane (TOL)/tazobactam (TAZ) plus amikacin (AMI) against Pseudomonas aeruginosa (PA) using simulated human dosing

Results of a Prospective Randomised Multicentre Trial to assess the Impact of Laboratory Based Rapid Diagnostics using MALDI-TOF Technology on Outcomes of Patients with Blood Stream Infection (BSI) (RAPIDO Study)

Reference No.

Document title

P1257

Pharmacodynamics of Amikacin Inhale studied in an in vitro pharmacokinetic model of infection

Bad bugs, no drugs and no ESKAPE

P1127

Screening neonates for Pseudomonas aeruginosa; does it help prevent infection in babies at risk?

Reference No.

Document title

EVO268

Epidemiology of Antibiotic Resistance of E.coli, S.aureus and P.aeruginosa Isolated From Bloodstream Infections (BSI) Across 5 Centres in England and Wales During 2010-2012

Reference No.

Document title

P1582

MIC distributions of MRSA to ceftaroline, vancomycin, teicoplanin and daptomycin: potential problems for routine susceptibility testing

Reference No.

Document title

P1821

Bactericidal Activity of Fosfomycin against NDM-1 producing Enterobacteriaceae

P676

Antimicrobial susceptibility testing of Listeria monocytogenes with EUCAST breakpoints: A multi‐laboratory study

P1624

Therapeutic drug monitoring of Daptomycin: a 4 year audit of levels from a UK clinical antibiotic service

Reference No.

Document title

P795Antibacterial effect of ceftaroline against MRSA and VISA strains studied in an in vitro pharmacokinetic model of infection

P729Impact of inoculum on the antibacterial effect of levofloxacin and moxifloxacin against S. pneumoniae strains with defined resistance mechanisms studied in an in vitro model of infection